Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD.~Exclusion Criteria:~* Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg (Type: EXPERIMENTAL): Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
- AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg (Type: EXPERIMENTAL): Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
- AZES Placebo/AZFD Lanabecestat 20 mg (Type: EXPERIMENTAL): Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
- AZES Placebo/AZFD Lanabecestat 50 mg (Type: EXPERIMENTAL): Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).